Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 1999; 81(05): 793-798
DOI: 10.1055/s-0037-1614572
DOI: 10.1055/s-0037-1614572
Rapid Communication
Identification of the Binding Site for an Alloantibody to von Willebrand Factor which Inhibits Binding to Glycoprotein Ib within the Amino-terminal Region Flanking the A1 Domain
Further Information
Publication History
Received
09 June 1998
Accepted after resubmission
27 January 1999
Publication Date:
09 December 2017 (online)
Summary
An alloantibody to von Willebrand factor (vWF) which developed in a Japanese boy with type 3 von Willebrand disease has been characterized. The antibody was non-precipitating IgG and the main subclasses were IgG2 and IgG4. The antibody inhibited completely ristocetin-induced platelet aggregation (RIPA) and high shear stress-induced platelet aggregation (SIPA). Its predominant inhibitory role was focused, therefore, on the interaction between vWF and platelet gycoprotein Ib. The antibody reacted with a 52/48 kDa tryptic fragment of vWF (residues 449-728). No reaction was seen, however, with either a 39/34 kDa dispase fragment (480-718) or a recombinant vWF fragment (residues 465-728). These findings suggested that the essential epitope resided in the amino-terminal flanking region of the A1 domain. We synthesized overlapping peptides corresponding to the region containing D3/A1 boundary. A peptide, residues 458-472, bound to the antibody and dose-dependently blocked the antibody binding to the 52/48 kDa fragment. The same peptide neutralized the inhibitory effect of the alloanti-body on SIPA. The data are consistent with the presence of an epitope within residues 458-472 which reacted with the 52/48 kDa fragment.
Furthermore, the specific component of the antibody, directed against residues 458-472, blocked vWF binding to GPIb in absence of exogenous agonist. Our results suggest that the region flanking the A1 domain plays an important role in regulating vWF binding to GPIb.
-
References
- 1 Ruggeri ZM, Zimmerman TS.. von Willebrand factor and von Willebrand disease.. Blood 1987; 70: 895-904.
- 2 Marti T, Rosselet SJ, Titani K, Walsh KA.. Identification of disulfide bridged substructures within human von Willebrand factor.. Biochemistry 1989; 26: 8099-109.
- 3 Krohl MH, Harris TS, Moake JL, Handin RI, Schafer AI.. von Willebrand factor binding to platelet GPIb initiates signals for platelet activation.. J Clin Invest 1991; 88: 1568-73.
- 4 De Marco L, Girolami A, Russel S, Ruggeri ZM. Interaction of asialo von Willebrand factor with glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and mediates platelet aggregation.. J Clin Invest 1985; 75: 1198-203.
- 5 Fujimura Y, Titani K, Holland LZ, Russel SR, Roberts JR, Elder JH, Ruggeri ZM, Zimmerman TS.. von Willebrand factor. A reduced and alkylated 52/48 kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib.. J Biol Chem 1986; 261: 381-5.
- 6 Fujimura Y, Usami Y, Titani K, Niinomi K, Nishio K, Takase T, Yoshioka A, Fukui H.. Studies on anti-von Willebrand factor (vWF) monoclonal antibody NMC-4. which inhibits both ristocetin- and botrocetin-induced vWF binding to platelet glycoprotein Ib.. Blood 1991; 77: 113-20.
- 7 Mohri H, Fujimura Y, Shima M, Yoshioka A, Houghton RA, Ruggeri ZM, Zimmerman TS.. Structure of the von Willebrand factor domain interacting with glycoprotein Ib.. J Biol Chem 1988; 263: 17901-4.
- 8 Sugimoto M, Mohri H, McClintock RA, Ruggeri ZM.. Identification of discontinuous von Willebrand sequences involved in complex formation with botrocetin: a model for regulation of von Willebrand factor binding to platelet glycoprotein Ib.. J Biol Chem 1988; 266: 18172-8.
- 9 Berndt MC, Ward CM, Booth WJ, Castaldi PA, Mazurov AV, Andrews RK.. Identification of aspartic acid-514 through glutamic acid-542 as a glycoprotein Ib-IX complex receptor recognition sequence in von Willebrand factor. Mechanism of modulation of von Willebrand factor by ristocetin and botrocetin.. Biochemistry 1992; 31: 11144-51.
- 10 Sugimoto M, Ricca G, Hrinda M, Schreiber AB, Searfoss GH, Bottini E, Ruggeri ZM.. Functional modulation of the isolated glycoprotein Ib binding domain of von Willebrand factor expressed in Escherichia coli.. Biochemistry 1991; 30: 5202-9.
- 11 Sugimoto M, Dent J, McClintock R, Ware J, Ruggeri ZM.. Analysis of structure-function relationships in the platelet membrane glycoprotein Ibbinding domain of von Willebrand’s factor by expression of deletion mutants.. J Biol Chem 1993; 268: 12185-92.
- 12 Matushita T, Sadler JE.. Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib.. J Biol Chem 1995; 270: 13406-14.
- 13 Sadler JE.. A revised classification of von Willebrand disease.. Thromb Haemost 1994; 71: 520-5.
- 14 Mannucci PM, Cattaneo M.. Alloantibodies in congenital von Willebrand disease.. Ric Clin Lab 1991; 21: 119-25.
- 15 Mannucci PM, Ruggeri ZM, Ciavarella N, Kazatchine MD, Moubray JF.. Precipitating antibodies to factor VIII/von Willebrand factor in von Willebrand disease: effects on replacement therapy.. Blood 1981; 57: 25-31.
- 16 Ruggeri ZM, Ciavarella N, Mannucci PM, Molinari A, Dammacco F, Lavergne JN, Meyer D.. Familial incidence of precipitating antibodies in von Willebrand’s disease: a study of four cases.. J Lab Clin Med 1979; 94: 60-75.
- 17 Lopez-Fernamdez MF, Martin R, Lopez-Berges C, Ramos F, de Bosch N. Battle J. Further specificity characterization of von Willebrand factor inhibitors developed in two patients with severe von Willebrand disease.. Blood 1988; 72: 116-2.
- 18 Maragall S, Castillo R, Ordinas A, Liendo F, Rodrigues M.. Inhibition of von Willebrand factor in von Willebrand disease.. Thromb Res 1979; 14: 495-500.
- 19 Mohri H, Yamazaki E, Suzuki Z, Takano T, Yokota S, Okubo T.. Autoantibody selectively inhibits binding of von Willebrand factor to glycoprotein Ib. Recognition site is located in the A1 loop of von Willebrand factor.. Thromb Haemost 1997; 77: 760-6.
- 20 Duke WW.. The reaction of blood platelets to hemorrhagic disease: Description of a method for determining the bleeding time and coagulation time and report of three cases of hemorrhagic disease relieved by transfusion.. J Am Med Assoc 1910; 55: 1185-91.
- 21 Hardisty RM, MacPherson JC.. A one-stage factor VIII (Anti-haemophilic globulin) assay and its use on venous and capillary plasma.. Thromb Diath Haemorrh 1962; 7: 215-29.
- 22 Cejka J.. Enzyme immunoassay for FVIII related antigen.. Clin Chem 1982; 28: 1356-8.
- 23 Allain JP, Cooper HA, Wagner RH, Brinkhaus KM.. Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand factor and platelet aggregating factor.. J Lab Clin Med 1975; 85: 318-28.
- 24 MacFarlane DE, Sttibe J, Kirby EP, Zucker MB, Grant RA, MacPherson J.. A method for assaying von Willebrand factor (Ristocetin cofactor).. Thromb Diath Haemorrh 1975; 34: 306-8.
- 25 Girma JP, Chopek MW, Titani K, Davie EH.. Limited proteolysis of human von Willebrand factor by staphylococcus aureus V-8 protease. Isolation and partial characterization of a platelet binding domain.. Biochemistry 1986; 25: 3156-67.
- 26 Andrews RK, Gormann JJ, Booth WJ, Corino GL, Castardi PA, Berndt MC.. Cross-linking of a monomeric 39/34 kDa dispase fragment of von Willebrand factor (Leu480/Val481-Gly718) to the N-terminal region of the a chain of membrane glycoprotein Ib on intact platelets with bis (sulfosuccinimidyl) suberate.. Biochemistry 1989; 28: 8326-36.
- 27 Houghten RA.. General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at the level of individual amino acid.. Proc Natl Acad Sci USA 1985; 82: 5131-5.
- 28 Turkova JJ.. Chromato. Library 12, Affinity Chromatography. Elsevier Scientific; Amsterdam: 1978: 246-363.
- 29 Sawamoto Y, Shima M, Yamamoto M, Kamisue S, Nakai H, Tanaka I, Hayashi K, Yoshioka A.. Measurement of anti-FIX IgG subclasses in Haemophilia B patients who developed inhibitors with episodes of allergic reactions to FIX concentrates.. Thromb Res 1996; 83: 279-86.
- 30 Friguet B, Chaffotte AF, Djavadi-Ohaniance L, Goldberg ME.. Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay.. J Immunol Methods 1985; 77: 305-19.
- 31 Ikeda Y, Handa M, Kawano K, Kamata T, Murata M, Yoshioka A, Anbo H, Kawai Y, Watanabe K, Itagaki I, Sakai K, Ruggeri ZM.. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress.. J Clin Invest 1991; 87: 1234-40.
- 32 Shima M, Ware J, Yoshioka A, Fukui H, Fulcher CA.. An arginine to cysteine amino acid substitution at a critical thrombin cleavage site in a dysfunctional factor VIII molecule.. Blood 1989; 74: 1612-7.
- 33 Amemiya Y, Miyahara J.. Imaging plate illuminates many fields.. Nature 1988; 336: 89-90.
- 34 Fulcher CA, de Graaf Mahoney S, Zimmerman TS.. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting.. Blood 1987; 69: 1475-80.
- 35 Mannucci PM, Meyer D, Ruggeri ZM, Koutts J, Ciavarella N, Lavergne JM.. Precipitating antibodies in von Willebrand disease.. Nature 1976; 262: 141-2.
- 36 Aalberse RC, van der Gaag R, van Leeuwen J.. Serologic aspects of IgG4 antibodies.. J Immunol 1993; 130: 722-6.
- 37 Girma JP, Ribba AS, Meyer D.. Structure-function relationship of the A1 domain of von Willebrand factor.. Thromb Haemost 1995; 74: 156-60.